| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Department of Neurology, Baylor College of Medicine, Houston, TX.
Received November 8, 1994. Accepted in final form February 3, 1995.
Address correspondence and reprint requests to Dr. Joseph Jankovic, Baylor College of Medicine, Department of Neurology, 6550 Fannin #1801, Houston, TX 77030.
Botulinum toxin antibodies (ABS) may be a reason why occasionally patients do not have a response to injections with botulinum toxin type A (BTX).We tested 86 patients with cervical or oromandibular dystonia for the presence of BTX ABS; 20 were positive and 66 were negative. All patients who tested positive had no response to BTX injections on at least two consecutive treatment sessions. When compared with 22 randomly selected patients with negative BTX ABS results, the patients with positive BTX ABS tests had an earlier age at onset (mean age: 31.8 plus minus 16.7 years versus 43.4 plus minus 10.5; p less than 0.05), higher mean dose per visit (249.2 plus minus 32.5 U versus 180.8 plus minus 68.7, p less than 0.0005), and higher total cumulative dose (mean dose: 1,709 plus minus 638 U versus 1,066 plus minus 938; p less than 0.01). Four out of five patients with positive ABS tests later had a response to botulinum toxin type F injections. Of 26 patients with negative BTX ABS results who were tested because of poor response on at least one visit, 21 had good response after subsequent injection and five had no effect. Except for young age at onset and higher dosages, there were no other factors that could reliably predict which patients would become immunoresistant to BTX type A injections. Treatment with alternate serotypes may offer clinical benefit to this group of patients. Absence of detectable BTX ABS may occur in patients with poor response to BTX injections because of inadequate dosage, injections of inappropriate muscles, or poor sensitivity of the BTX ABS bioassay.
NEUROLOGY 1995;45: 1743-1746
This article has been cited by other articles:
|
|
 |
|
  G. Kranz, T. Sycha, B. Voller, G. S. Kranz, P. Schnider, and E. Auff Neutralizing antibodies in dystonic patients who still respond well to botulinum toxin type A Neurology, January 8, 2008; 70(2): 133 - 136. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ramachandran and D. M. Eastwood Botulinum toxin and its orthopaedic applications J Bone Joint Surg Br, August 1, 2006; 88-B(8): 981 - 987. [Full Text] [PDF]
|
|
|
|
 |
|
 R E Morton, J Hankinson, and J Nicholson Botulinum toxin for cerebral palsy; where are we now? Arch. Dis. Child., December 1, 2004; 89(12): 1133 - 1137. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ghazizadeh and M. Nikzad Botulinum Toxin in the Treatment of Refractory Vaginismus Obstet. Gynecol., November 1, 2004; 104(5): 922 - 925. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Jankovic, K.D. Vuong, and J. Ahsan Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia Neurology, April 8, 2003; 60(7): 1186 - 1188. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C Ertekin, I Aydogdu, Y Secil, N Kiylioglu, S Tarlaci, and T Ozdemirkiran Oropharyngeal swallowing in craniocervical dystonia J. Neurol. Neurosurg. Psychiatry, October 1, 2002; 73(4): 406 - 411. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Munchau, C D Good, S McGowan, N P Quinn, J D Palmer, and K P Bhatia Prospective study of swallowing function in patients with cervical dystonia undergoing selective peripheral denervation J. Neurol. Neurosurg. Psychiatry, July 1, 2001; 71(1): 67 - 72. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Munchau, J. D. Palmer, D. Dressler, J. D. O'Sullivan, K. L. Tsang, M. Jahanshahi, N. P. Quinn, A. J. Lees, and K. P. Bhatia Prospective study of selective peripheral denervation for botulinum-toxin resistant patients with cervical dystonia Brain, April 1, 2001; 124(4): 769 - 783. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Heckmann, M. Schaller, S. Breit, and G. Plewig Evaluation of Therapeutic Success of Hyperhidrosis Therapy Arch Dermatol, January 1, 2001; 137(1): 94 - 94. [Full Text] [PDF]
|
|
|
|
 |
|
 S. P. Christiansen, A. Sandnas, R. Prill, R. J. Youle, and L. K. McLoon Acute Effects of the Skeletal Muscle-Specific Immunotoxin Ricin-mAb 35 on Extraocular Muscles of Rabbits Invest. Ophthalmol. Vis. Sci., October 1, 2000; 41(11): 3402 - 3409. [Abstract] [Full Text]
|
|
|
|
|
|
E. C DAVIS and M. P BARNES Botulinum toxin and spasticity J. Neurol. Neurosurg. Psychiatry, August 1, 2000; 69(2): 143 - 147. [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Smith and C. N. Ford Resistance to Botulinum Toxin Injections for Spasmodic Dysphonia Arch Otolaryngol Head Neck Surg, April 1, 2000; 126(4): 533 - 535. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. F. Brin, M. F. Lew, C. H. Adler, C. L. Comella, S. A. Factor, J. Jankovic, C. O'Brien, J. J. Murray, J. D. Wallace, A. Willmer-Hulme, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia Neurology, October 22, 1999; 53(7): 1431 - 1431. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A Hanna, J. Jankovic, and A. Vincent Comparison of mouse bioassay and immunoprecipitation assay for botulinum toxin antibodies J. Neurol. Neurosurg. Psychiatry, May 1, 1999; 66(5): 612 - 616. [Abstract] [Full Text]
|
|
|
|
|
|
J. JANKOVIC Re-emergence of surgery for dystonia J. Neurol. Neurosurg. Psychiatry, October 1, 1998; 65(4): 434 - 434. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
